Trial
NCT01185366
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
Novartis
Condition
Kidney Cancer
Intervention
Everolimus
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-28